CD47 and hepatocellular carcinoma: From the data presented, it is evident that the integration of nanotechnology into PDT offers several notable advantages for HCC management: (1) enhanced efficacy of PSs; (2) improved tumor tissue penetration; (3) targeted drug delivery at the tissue, cellular, or subcellular level—as exemplified by platforms such as CD47-functionalized exosomes (Er/RB@Exos^CD47)[29], which represent an innovative approach to targeted delivery; (4) enabling sustained drug release; (5) tumor-targeted imaging capabilities.